Other languages Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-01 EDT			5-day change	1st Jan Change
2.86 ^USD	-2.39%		+7.92%	+113.43%

03-20	Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024
03-20	Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20
Trevi Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-20
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio? for Chronic Cough in Idiopathic Pulmonary Fibrosis	12-05
Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio?? for Refractory Chronic Cough	11-02
Trevi Therapeutics, Inc. Announces Results from Phase 2b/3 Prism Open-Label Extension Study of Haduvio in Prurigo Nodularis	23-10-13
Trevi Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Trevi Therapeutics Files $200 Million Mixed Shelf	23-06-30
Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Trevi Therapeutics Gets Patent Notice of Allowance for Method to Treat Chronic Cough in Idiopathic Pulmonary Fibrosis	23-03-08
Trevi Therapeutics, Inc. Announces Allowance for U.S. Patent Application Covering Use of Haduvio (Nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis	23-03-08
Trevi Therapeutics, Inc. Appoints David Clark as Chief Medical Officer	22-11-14
Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10
Trevi Therapeutics Prices $55 Million Common Stock Offering	22-09-23
Trevi Therapeutics Launches Common Stock Offering; Shares Down After Hours	22-09-22
Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis	22-09-19
Trevi Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11
Sector Update: Health Care Stocks Climb Premarket Wednesday	22-06-29
Sector Update: Health Care	22-06-29
Trevi Therapeutics Says Phase 2b/3 Trial Shows Positive Results for Skin Disease Treatment; Shares Rise Pre-Bell	22-06-29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Other languages

Filters